This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Danial, N. N. Search for Related Content PubMed PubMed Citation Articles by Danial, N. N. Related Collections Cellular Pathobiology Cellular Pathobiology: Proliferation, Senescence, and Death

BCL-2 Family Proteins: Critical Checkpoints of Apoptotic Cell Death

Author's Affiliation: Department of Pathology, Harvard Medical School and Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts

Requests for reprints: Nika N. Danial, Department of Cancer Biology, Dana-Farber Cancer Institute, 44 Binney Street, Smith 756, Boston, MA 02115. Phone: 617-632-6436; E-mail: nika_danial{at}dfci.harvard.edu.

Abstract

Apoptosis is a morphologically distinct form of programmed cell death essential for normal development and tissue homeostasis. Aberrant regulation of this pathway is linked to multiple human diseases, including cancer, autoimmunity, neurodegenerative disorders, and diabetes. The BCL-2 family of proteins constitutes a critical control point in apoptosis residing immediately upstream of irreversible cellular damage, where family members control the release of apoptogenic factors from mitochondria. The cardinal member of this family, BCL-2, was originally discovered as the defining oncogene in follicular lymphomas, located at one reciprocal breakpoint of the t(14;18) (q32;q21) chromosomal translocation. Since this original discovery, remarkable efforts marshaled by many investigators around the world have advanced our knowledge of the basic biology, molecular mechanisms, and therapeutic targets in the apoptotic pathway. This review highlights findings from many laboratories that have helped uncover some of the critical control points in apoptosis. The emerging picture is that of an intricate cellular machinery orchestrated by tightly regulated molecular interactions and conformational changes within BCL-2 family proteins that ultimately govern the cellular commitment to apoptotic death.

This article has been cited by other articles:

				E. J. Benz Jr., D. G. Nathan, R. K. Amaravadi, and N. N. Danial Targeting the Cell Death-Survival Equation Clin. Cancer Res., December 15, 2007; 13(24): 7250 - 7253. [Full Text] [PDF]

				G. L. Verdine and L. D. Walensky The Challenge of Drugging Undruggable Targets in Cancer: Lessons Learned from Targeting BCL-2 Family Members Clin. Cancer Res., December 15, 2007; 13(24): 7264 - 7270. [Abstract] [Full Text] [PDF]

				R. K. Amaravadi and C. B. Thompson The Roles of Therapy-Induced Autophagy and Necrosis in Cancer Treatment Clin. Cancer Res., December 15, 2007; 13(24): 7271 - 7279. [Abstract] [Full Text] [PDF]

				O. Rixe and T. Fojo Is Cell Death a Critical End Point for Anticancer Therapies or Is Cytostasis Sufficient? Clin. Cancer Res., December 15, 2007; 13(24): 7280 - 7287. [Abstract] [Full Text] [PDF]